LYKALABSNSELyka Labs Limited· PharmaceuticalsMediumNeutral
Announced Tue, 17 Mar · 16:35 IST

Lyka Labs Limited has informed the Exchange about General Updates

Nclt Scheme FiledStrategic Transactions View source PDF

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.1%1-day move
₹52.50
prior close
₹51.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+4.1+4.3+7.4+6.4-0.1+4.8-5.7-6.4-2.6-12.9+10.4+10.5+11.6+32.3
Up moveDown movePending
AI summary

The NCLT Ahmedabad Bench has approved the Scheme of Amalgamation merging Lyka Exports Limited (unlisted transferor) into Lyka Labs Limited (listed transferee) under Sections 230-232 of the Companies Act, 2013, with the order pronounced on 16th March 2026. The appointed date for the merger is 1st April 2022, meaning the merger is effective retrospectively from FY23. Upon implementation, Lyka Exports will be dissolved without winding up, and all its assets, liabilities, employees, and pending proceedings will transfer to Lyka Labs. The company must file the certified NCLT order with the Registrar of Companies via e-form INC-28 within 30 days, and pay Rs. 50,000 in legal fees to the Regional Director. The order preserves all rights of the Income Tax Department to pursue tax liabilities and does not grant exemption from stamp duty or other statutory dues.

Likely market impact

This is a key milestone for Lyka Labs as the merger now awaits only ROC filing to become effective. Since Lyka Exports is an unlisted group entity, the merger is expected to be a share-swap/restructuring exercise with limited direct impact on share count or EPS. Shareholders should watch for the swap ratio announcement and any incremental tax/liability disclosures once filings are completed.